書籍詳細

環境

P.6 掲載の参考文献

• 1) Rappaport SM, Smith MT. Science 2010;330:460-1.
  pubmed

• 2) Wadhwa PD et al. Semin Reprod Med 2009;27:358-68.
  pubmed

• 3) Martin EM, Fry RC. Annu Rev Public Health 2018;39:309-33.
  pubmed

• 4) Leenen FA et al. Clin Epigenetics 2016;8:92.
  pubmed

• 5) Hannum G et al. Mol Cell 2013;49:359-67.
  pubmed

• 6) Horvath S, Raj K. Nat Rev Genet 2018;19:371-84.

• 7) Wang M, Lemos B. Genome Res 2019;29:325-33.
  pubmed

• 8) Feinberg AP. N Engl J Med 2018;378:1323-34.
  pubmed

• 9) Declerck K, Vanden Berghe W. Mech Ageing Dev 2018;174:18-29.
  pubmed

• 10) Ciccarone F et al. Mech Ageing Dev 2018;174:3-17.
  pubmed

• 11) Quach A et al. Aging(Albany NY)2017;9:419-46.
  pubmed

• 12) Petkovich DA et al. Cell Metab 2017;25:954-60. e6.

• 13) Garrett-Bakelman FE et al. The NASA Twins Study:A multidimensional analysis of a year-long human spaceflight. Science 2019;364(6436). pii:eaau8650. doi:10.1126/science.aau8650.

• 14) Pan WH et al. Lancet 1995;345:353-5.
  pubmed

• 15) Doughty KN et al. Curr Cardiol Rep 2017;19:116.

• 16) Chen R et al. BMJ 2018;363:k4306.
  pubmed

• 17) Pickering TG. J Hum Hypertens 1997;11 Suppl 1:S9-18.

• 18) Zhao H et al. J Hypertens 2019;37:504-12.

• 19) Cohen AJ et al. Lancet 2017;389:1907-18.
  pubmed

• 20) Michikawa T et al. Japanese Nationwide Study on the Association between Short-term Exposure to Particulate Matter and Mortality. J Epidemiol 2018. doi:10.2188/jea.JE20180122.[Epub ahead of print]

• 21) Somineni HK et al. J Allergy Clin Immunol 2016;137:797-805.e5.

• 22) Hu Y et al. N Engl J Med 2018;379:623-32.

• 23) van Dongen J et al. Nat Commun 2016;7:11115.
  pubmed

• 24) Oberg M et al. Lancet 2011;377:139-46.
  pubmed

• 25) 山田秀和. 見た目のアンチエイジング研究. 皮膚科領域. 医学のあゆみ2017;261:623-6.

• 26) Vandiver AR et al. Genome Biol 2015;16:80.
  pubmed

• 27) Shan Z et al. BMJ 2018;363:k4641.
  pubmed

• 28) Gale CR et al. Clin Epigenetics 2018;10:4.
  pubmed

• 29) Wang T et al. Genome Biol 2017;18:57.
  pubmed

各領域の最新情報

P.13 掲載の参考文献

• 1) 大内尉義, 秋山弘子編. 新老年学<第3版>. 東京大学出版会;2010.

• 2) 日本老年医学会編. <改訂第3版>老年医学テキスト. メジカルビュー社;2008.

• 3) 島村宗尚・他. 脳血管のアンチエイジングと認知症予防. 分子脳血管病 2016;15(1):14-8.
  Medical*Online

• 4) 厚生労働省. 平成28年国民生活基礎調査の概況. 2017. (https://www.mhlw.go.jp/toukei/saikin/hw/k-tyosa/k-tyosa16/dl/16.pdf)

• 5) 山本幹枝・他. 認知症有病率の時代的推移-洋の東西の比較. 日本老年医学会雑誌2018;55(4):547-52.

• 6) Jack CR Jr et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9(1):119-28.
  pubmed

• 7) 「認知症疾患診療ガイドライン」作成委員会編. 認知症疾患診療ガイドライン2017. 医学書院;2017.

• 8) Livingston G et al. Dementia prevention, intervention, and care. Lancet 2017;390(10113):2673-734.
  pubmed

• 9) 島田裕之. コグニサイズと認知機能アンチエイジング. アンチ・エイジング医学 2016;12(4):463-8.
  Medical*Online

• 10) 大塚礼・他. 栄養と認知機能アンチエイジング. アンチ・エイジング医学 2016;12(4):469-74.
  Medical*Online

• 11) 田平 武. サプリメントと認知機能アンチエイジング. アンチ・エイジング医学 2016;12(4):481-6.
  Medical*Online

• 12) Irwin MR, Vitiello MV. Implications of sleep disturbance and inflammation for Alzheimer's disease dementia. Lancet Neurol 2019;18(3):296-306.
  pubmed

P.19 掲載の参考文献

• 1) Kirkwood TB, Austad SN. Why do we age? Nature. 2000 Nov 9;408(6809):233-8.

• 2) Roger VL et al. Heart disease and stroke statistics--2011 update:a report from the American Heart Association. Circulation..

• 3) Lakatta EG. Arterial and cardiac aging:major shareholders in cardiovascular disease enterprises:Part III:cellular and molecular clues to heart and arterial aging. Circulation. 2003 Jan 28;107(3):490-7.

• 4) Lakatta EG, Levy D. Arterial and cardiac aging:major shareholders in cardiovascular disease enterprises:Part II:the aging heart in health:links to heart disease. Circulation. 2003 Jan 21;107(2):346-54.

• 5) Dai DF, Rabinovitch PS. Cardiac aging in mice and humans:the role of mitochondrial oxidative stress. Trends Cardiovasc Med. 2009 Oct;19(7):213-20.

• 6) Ferder L et al.. Effects of angiotensin-converting enzyme inhibition on mitochondrial number in the aging mouse. Am J Physiol. 1993 Jul;265(1 Pt 1):C15-8.

• 7) Basso N et al. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul Pept. 2005 Jun 30;128(3):247-52.

• 8) Ferder L et al. Biomolecular changes in the aging myocardium:the effect of enalapril. Am J Hypertens. 1998 Nov;11(11 Pt 1):1297-304.

• 9) Benigni A et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest. 2009 Mar;119(3):524-30.
  pubmed

• 10) Oliverio MI and Coffman TM. Angiotensin-II-receptors:new targets for antihypertensive therapy. Clin Cardiol. 1997 Jan;20(1):3-6.
  pubmed

• 11) Brack A S et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science. 2007 Aug 10;317(5839):807-10.

• 12) Loffredo FS et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell. 2013 May 9;153(4):828-39.

• 13) Conboy IM et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature. 2005 Feb 17;433(7027):760-4.

• 14) White BD et al. Effects of age on the feeding response to moderately low dietary protein in rats. Physiol Behav. 2000 Mar;68(5):673-81.
  pubmed

• 15) Naito AT et al. Complement C1q activates canonical Wnt signaling and promotes aging-related phenotypes. Cell. 2012 Jun 8;149(6):1298-313.

• 16) Bergmann MW. WNT signaling in adult cardiac hypertrophy and remodeling:lessons learned from cardiac development. Circ Res. 2010 Nov 12;107(10):1198-208.

• 17) Nakagawa A et al.. Activation of endothelial β-catenin signaling induces heart failure. Sci Rep. 2016 May 5;6:25009.

• 18) Okada K et al. Circ Heart Fail. 2015 Jul;8(4):799-808.
  pubmed

• 19) et al. Complement C1q-induced activation of β-catenin signalling causes hypertensive arterial remodelling. Nat Commun. 2015 Feb 26;6:6241.

• 20) Yabumoto C et al. Angiotensin II receptor blockade promotes repair of skeletal muscle through down-regulation of aging-promoting C1q expression. Sci Rep. 2015 Sep 25;5:14453.

• 21) Kamo T et al. Pleiotropic Effects of Angiotensin II Receptor Signaling in Cardiovascular Homeostasis and Aging. Int Heart J. 2015 May 13;56(3):249-54.

P.26 掲載の参考文献

• 1) Imai E et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009;13(6):621-30.
  pubmed

• 2) Lindeman RD et al. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33(4):278-85.

• 3) Wang X et al. Age, kidney function, and risk factors associate differently with cortical and medullary volumes of the kidney. Kidney Int 2014;85(3):677-85.
  pubmed

• 4) O'Neill WC. Structure, not just function. Kidney Int 2014;85(3):503-5.

• 5) Rule AD et al. Characteristics of renal cystic and solid lesions based on contrast-enhanced computed tomography of potential kidney donors. Am J Kidney Dis 2012;59(5):611-8.
  pubmed

• 6) Rule AD et al. The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med 2010;152(9):561-7.
  pubmed

• 7) Wharram BL et al. Podocyte depletion causes glomerulosclerosis:diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005;16(10):2941-52.
  pubmed

• 8) Wiggins RC. The spectrum of podocytopathies:a unifying view of glomerular diseases. Kidney Int 2007;71(12):1205-14.
  pubmed

• 9) Hodgin JB et al. Glomerular Aging and Focal Global Glomerulosclerosis:A Podometric Perspective. J Am Soc Nephrol 2015;26(12):3162-78.
  pubmed

• 10) Kremers WK et al. Distinguishing age-related from disease-related glomerulosclerosis on kidney biopsy:the Aging Kidney Anatomy study. Nephrology, dialysis, transplantation:official publication of the European Dialysis and Transplant Association- European Renal Association 2015;30(12):2034-9.
  pubmed

• 11) Hommos MS et al. Global glomerulosclerosis with nephrotic syndrome;the clinical importance of age adjustment. Kidney Int 2018;93(5):1175-82.
  pubmed

• 12) Denic A et al. Single-Nephron Glomerular Filtration Rate in Healthy Adults. N Engl J Med 2017;376(24):2349-57.
  pubmed

• 13) Anderson S et al. Acute kidney injury in older adults. J Am Soc Nephrol 2011;22(1):28-38.
  pubmed

• 14) Ishani A et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009;20(1):223-8.
  pubmed

• 15) Yang L et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010;16(5):535-43.
  pubmed

• 16) Ferenbach DA, Bonventre JV. Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat Rev Nephrol 2015;11(5):264-76.
  pubmed

• 17) Sato Y, Yanagita M. Immune cells and inflammation in AKI to CKD progression. Am J Physiol Renal Physiol 2018;315(6):F1501-F12.
  pubmed

• 18) Duewell P et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464(7293):1357-61.
  pubmed

• 19) Vandanmagsar B et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011;17(2):179-88.
  pubmed

• 20) Bai H et al. Downregulation of signal transduction and STAT3 expression exacerbates oxidative stress mediated by NLRP3 inflammasome. Neural Regen Res 2018;13(12):2147-55.
  pubmed

• 21) Franceschi C et al. Inflammaging:a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 2018;14(10):576-90.
  pubmed

• 22) Sato Y et al. Heterogeneous fibroblasts underlie age-dependent tertiary lymphoid tissues in the kidney. JCI Insight 2016;1(11):e87680.
  pubmed

• 23) Pei G et al. Renal interstitial infiltration and tertiary lymphoid organ neogenesis in IgA nephropathy. Clin J Am Soc Nephrol 2014;9(2):255-64.
  pubmed

• 24) Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell 2014;157(5):1013-22.
  pubmed

• 25) Franceschi C et al. Inflammaging and 'Garb-aging'. Trends in endocrinology and metabolism:TEM 2017;28(3):199-212.

• 26) Furman D et al. Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. Nat Med 2017;23(2):174-84.
  pubmed

• 27) Pereira RA et al. Sarcopenia in chronic kidney disease on conservative therapy:prevalence and association with mortality. Nephrology, dialysis, transplantation:official publication of the European Dialysis and Transplant Association-European Renal Association 2015;30(10):1718-25.
  pubmed

• 28) Chang SF, Lin PL. Frail phenotype and mortality prediction:a systematic review and meta-analysis of prospective cohort studies. Int J Nurs Stud 2015;52(8):1362-74.
  pubmed

• 29) Moorthi RN, Avin KG. Clinical relevance of sarcopenia in chronic kidney disease. Curr Opin Nephrol Hypertens 2017;26(3):219-28.
  pubmed

• 30) Ballew SH et al. Frailty, Kidney Function, and Polypharmacy:The Atherosclerosis Risk in Communities(ARIC)Study. Am J Kidney Dis 2017;69(2):228-36.
  pubmed

• 31) Sato E et al. Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease. Sci Rep 2016;6:36618.
  pubmed

• 32) Bano G et al. Inflammation and sarcopenia:A systematic review and meta-analysis. Maturitas 2017;96:10-5.
  pubmed

• 33) Peterson MJ et al. Physical activity as a preventative factor for frailty:the health, aging, and body composition study. J Gerontol A Biol Sci Med Sci 2009;64(1):61-8.
  pubmed

• 34) Cheema BS et al. Effect of progressive resistance training on measures of skeletal muscle hypertrophy, muscular strength and health-related quality of life in patients with chronic kidney disease:a systematic review and meta-analysis. Sports Med 2014;44(8):1125-38.
  pubmed

P.33 掲載の参考文献

• 1) Matsumoto S, Kakizaki H. Causative significance of bladder blood flow in lower urinary tract symptoms. Int J Urol 2012;19(1):20-5.

• 2) 松本成史. 特集:高齢者によくみられる泌尿器疾患. Seminar 6. 排尿障害は血流障害と大いに関係する疾患である. Geriatric Medicine 2017;55(4):409-12.

• 3) 松本成史. "State of the Art" 膀胱血流と下部尿路機能障害. Urology Today. 2014;21(3):124-9.

• 4) Matsumoto S et al. The functional and structural response to distention of the rabbit whole bladder in vitro. J Urol 2002;168(6):2677-81.
  pubmed

• 5) Matsumoto S et al. Structural and vascular response of normal and obstructed rabbit whole bladders to distension. Urology 2003;62(6):1129-33.
  pubmed

• 6) Greenland JE, Brading AF. Urinary bladder blood flow changes during the micturition cycle in a conscious pig model. J Urol 1996;156(5):1858-61.

• 7) Greenland JE, Brading AF. The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J Urol 2001;165(1):245-8.
  pubmed

• 8) Saito M et al. Real-Time Monitoring of Blood flow and Intravesical Pressure in the Rat Bladder. Low Urin Tract Symptoms 2011;3(2):76-8.
  pubmed

• 9) Greenland JE et al. The effect of bladder outlet obstruction on tissue oxygen tension and blood flow in the pig bladder. BJU Int 2000;85(9):1109-14.
  pubmed

• 10) Ponholzer A et al. The association between vascular risk factors and lower urinary tract symptoms in both sexes. Eur Urol 2006;50(3):581-6.
  pubmed

• 11) Motoya T et al. The impact of abdominal aortic calcification and visceral fat obesity on lower urinary tract symptoms in patients with benign prostatic hyperplasia. Int Urol Nephrol 2014;46(10):1877-81.
  pubmed

• 12) Persson K et al. Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol 1998;275(4):R1366-73.
  pubmed

• 13) McVary KT et al. Autonomic nervous system overactivity in men LUTS secondary to BPH. J Urol 2005;174(4 Pt 1):1327-433.

• 14) Bursztyn M et al. Usefulness of nocturia as a mortality risk factor for coronary heart disease among persons born in 1920 or 1921. Am J Cardiol 2006;98(10):1311-5.
  pubmed

• 15) Asplund R. Mortality in the elderly in relation to nocturnal micturition. BJU Int 1999;84(3):297-301.
  pubmed

• 16) Azadzoi KM et al. Overactivity and structural changes in the chronically ischemic bladder. J Urol 1999;162(5):1768-78.
  pubmed

• 17) Yoshida M et al. The effects of chronic hyperlipidemia on bladder function in myocardial infarction-prone Watanabe heritable hyperlipidemic(WHHLMI)rabbits. Neurourol Urodyn 2010;29(7):1350-4.
  pubmed

• 18) Pinggera GM et al. Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men:assessment using colour Doppler ultrasonography. BJU Int 2008;102(4):470-4.
  pubmed

• 19) De EJ et al. Pelvic ischemia is measurable and symptomatic in patients with coronary artery disease:a novel application of dynamic contrast-enhanced magnetic resonance imaging. J Sex Med 2008;5(11):2635-45.
  pubmed

• 20) Bratslavsky G et al. Reperfusion injury of the rat bladder is worse than ischemia. J Urol 2003;170(5):2086-90.
  pubmed

• 21) Das AK et al. Effect of doxazosin on rat urinary bladder function after partial outlet obstruction. Neurourol Urodyn 2002;21(2):160-6.
  pubmed

• 22) Okutsu H et al. Effects of tamsulosin on bladder blood flow and bladder function in rats with bladder outlet obstruction. Urology 2010;75(1):235-40.
  pubmed

• 23) Okutsu H et al. Effect of tamsulosin on bladder blood flow and bladder function in a rat model of bladder over distention/emptying induced bladder overactivity. J Urol 2011;186(6):2470-7.

• 24) Pinggera GM et al. alpha-Blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms. BJU Int 2008;101(3):319-24.
  pubmed

• 25) Matsumoto S et al. Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model. BJU Int 2009;103(7):987-90.

• 26) Matsumoto S et al. Chronic treatment with a PDE5 inhibitor increases contractile force of normal bladder in rats. Int Urol Nephrol 2010;42(1):53-6.
  pubmed

• 27) Matsumoto S et al. Edaravone protects against ischemia/reperfusion-induced functional and biochemical changes in rat urinary bladder. Urology 2005;66(4):892-6.
  pubmed

• 28) Matsumoto S et al. The effect of vitamin E on the response of rabbit bladder smooth muscle to hydrogen peroxide. Mol Cell Biochem 2003;254(1-2):347-51.
  pubmed

• 29) Abrams P et al. The standardisation of terminology of lower urinary tract function:report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78.
  pubmed

• 30) 本間之夫・他. 下部尿路機能に関する用語基準:国際禁制学会標準化部会報告. 日本排尿機能学会誌 2003;14:278-89.
  Medical*Online

• 31) Yang PJ et al. Duration of urination does not change with body size. PNAS 2014;111(33):11932-7.

• 32) 松本成史. 神経科学の素朴な疑問QUESTION 排尿時間はどの動物でも21秒だというのは本当ですか? Clinical Neuroscience 2019;37(1):125.

P.41 掲載の参考文献

• 1) 太田博明. 乳幼児期から思春期にかけての骨発育のスパート. CLINICAL CALCIUM 2019;29(1):9-17.

• 2) 網塚憲生・他. モデリングとリモデリングの違いは何ですか. 「骨」を知る53の質問-ウェルエイジングをサポートするために-. 太田博明編. 医薬ジャーナル社;2015:24-7.

• 3) NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285(6):785-95.
  pubmed

• 4) Parfitt AM. The coupling of bone formation to bone resorption:a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res 1982;4(1):1-6.

• 5) LeBlanc A et al. Bone mineral and lean tissue loss after long duration space flight. J Musculoskelet Neuronal Interact 2000;1(2):157-60.
  pubmed

• 6) Hauschka PV et al. Osteocalcin and matrix Gla protein:vitamin K-dependent proteins in bone. Physiol Rev 1989;69(3):990-1047.
  pubmed

• 7) Lee NK et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007;130(3):456-69.
  pubmed

• 8) Ferron M et al. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A 2008;105(13):5266-70.
  pubmed

• 9) Ferron M et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010;142(2):296-308.
  pubmed

• 10) Fulzele K et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 2010;142(2):309-19.
  pubmed

• 11) Rosen CJ et al. No bones about it:insulin modulates skeletal remodeling. Cell 2010;142(2):198-200.
  pubmed

• 12) 骨粗鬆症の予防と治療ガイドライン2015年版;2015. p.9.

• 13) 溝上顕子・他. オステオカルシンとインスリン分泌. 日本薬理学雑誌 2015;145(4):201-5.
  Medical*Online

• 14) 溝上顕子・他. オステオカルシンとエネルギー代謝. 骨粗鬆治療 2017;16(1):33-8.

P.49 掲載の参考文献

• 1) 井出吉信. 第2章 摂食・嚥下のメカニズム. 植松 宏. セミナーわかる!摂食・嚥下リハビリテーションI 評価法と対処法. 医歯薬出版;2005. p.14-31.

• 2) 阪上雅史. 味覚障害の診断と治療. 日本耳鼻咽喉科学会会報2012;115:8-13.

• 3) Helen Whelton. 第1章 序説:唾液腺の解剖と生理. 渡部 茂監訳. 唾液 歯と口腔の健康 原著第3版. 医歯薬出版;1997. p.1-10.

• 4) 阪井丘芳, 斎藤一郎. 特集:口腔機能のアンチエイジング. Anti-Aging Medicine 2015;11(2):19-66.

• 5) 奥野健太郎. 第1章 基礎知識編. 歯科医師の歯科医師による歯科医師のための睡眠時無呼吸症候群の口腔内装置治療. 阪井丘芳. 医歯薬出版;2014. p.7-12.

• 6) Wilcox I et al. "Syndrome Z":the interaction of sleep apnea, vascular risk factors and heart disease. Thorax 1998;53 Suppl 3:S25-8.

• 7) 野原幹司, 阪井丘芳. 第1章 摂食機能療法とは. 前田芳信, 阪井丘芳. 開業医のための摂食・嚥下機能改善と装置の作り方超入門. クインテッセンス;2013. p.10-20.

• 8) Orui T et al. A new therapy for Alzheimer's disease. Geriatr Gerontol Int 2004;4(2):123-5.

• 9) 山岡稔・他. Fiberscopeによる鼻咽腔閉鎖運動の観察法. 日本口腔外科学会雑誌 1972;18:13-7.

P.58 掲載の参考文献

• 1) Uemura N et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345(11):784-9.
  pubmed

• 2) Ohfuji S et al. Pre-illness isoflavone consumption and disease risk of ulcerative colitis:a multicenter case-control study in Japan. PloS One 2014;9(10):e110270.

• 3) Uchiyama K et al. Peptidomic analysis via one-step direct transfer technology for colorectal cancer biomarker discovery. J Proteomics Bioinform 2015:S5.

• 4) Uchiyama K et al. Serum metabolomics analysis for early detection of colorectal cancer. J Gastroenterol 2017;52(6)677-94.
  pubmed

• 5) Uchiyama K et al. Selected reaction monitoring for colorectal cancer diagnosis using a set of five serum peptides identified by BLOTCHIP(R) -MS analysis. J Gastroenterol 2018;53(11):1179-85.

• 6) Aoi W et al. A novel myokine, secreted protein acidic and rich in cysteine(SPARC), suppresses colon tumorigenesis via regular exercise. Gut 2013;62(6):882-9.

• 7) Meester RG et al. Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening:A Microsimulation Model. Jama 2015;313(23):2349-58.
  pubmed

• 8) Corley DA et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl Med 2014;370(14):1298-306.
  pubmed

• 9) Mima K et al. Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location. Clin Transl Gastroenterol 2016;7(11):e200.
  pubmed

• 10) Mehta RS et al. Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by Fusobacterium nucleatum in Tumor Tissue. JAMA Oncol 2017;3(7):921-7.
  pubmed

• 11) Komiya Y et al. Patients with colorectal cancer have identical strains of Fusobacterium nucleatum in their colorectal cancer and oral cavity. Gut 2018. pii:gutjnl-2018-316661. doi:10.1136/gutjnl-2018-316661.[Epub ahead of print]

• 12) Fan Y et al. Meta-analysis of the association between the inflammatory potential of diet and colorectal cancer risk. Oncotarget 2017;8(35):59592-600.
  pubmed

• 13) Liu B et al. Western diet feeding influences gut microbiota profiles in apoE knockout mice. Lipids Health Dis 2018;17(1):159.
  pubmed

• 14) Cho YA et al. Inflammatory Dietary Pattern, IL-17F Genetic Variant, and the Risk of Colorectal Cancer. Nutrients 2018;10(6). pii:E724. doi:10.3390/nu10060724.

• 15) Tabung FK et al. Development and Validation of an Empirical Dietary Inflammatory Index. J Nutr 2016;146(8):1560-70.
  pubmed

• 16) Tabung FK et al. Association of Dietary Inflammatory Potential With Colorectal Cancer Risk in Men and Women. JAMA Oncol 2018;4(3):366-73.
  pubmed

• 17) Liu L et al. Diets That Promote Colon Inflammation Associate With Risk of Colorectal Carcinomas That Contain Fusobacterium nucleatum. Clin Gastroenterol Hepatol 2018;16(10):1622-31. e3.

P.63 掲載の参考文献

• 1) Kurita M et al. A therapeutic strategy based on histological assessment of hyperpigmented skin lesions in Asians. J Plast Reconstr Aesthet Surg 2009;62:955-63.
  pubmed

• 2) Mashiko T et al. Semi-permanent volumization by an absorbable filler:Onlay injection technique to the bone. Plast Reconstr Surg Glob Open 2013;1:e4-14.

P.68 掲載の参考文献

• 1) Kobayashi K et al. Mitochondrial superoxide in osteocytes perturbs canalicular networks in the setting of age-related osteoporosis. Sci Rep 2015;5:9148.
  pubmed

• 2) Aigner T et al. Large-scale gene expression profiling reveals major pathogenetic pathways of cartilage degeneration in osteoarthritis. Arthritis Rheum 2006;54(11):3533-44.
  pubmed

• 3) Ruiz-Romero C et al. Mitochondrial dysregulation of osteoarthritic human articular chondrocytes analyzed by proteomics:a decrease in mitochondrial superoxide dismutase points to a redox imbalance. Mol Cell Proteomics 2009;8(1):172-89.
  pubmed

• 4) Scott JL et al. Superoxide dismutase downregulation in osteoarthritis progression and end-stage disease. Ann Rheum Dis 2010;69(8):1502-10.
  pubmed

• 5) Koike M et al. Mechanical overloading causes mitochondrial superoxide and SOD2 imbalance in chondrocytes resulting in cartilage degeneration. Sci Rep 2015;5:11722.
  pubmed

• 6) Short KR et al. Decline in skeletal muscle mitochondrial function with aging in humans. Proc Nat Acad Sci U S A 2005;102(15):5618-23.
  pubmed

• 7) Kuwahara H et al. Oxidative stress in skeletal muscle causes severe disturbance of exercise activity without muscle atrophy. Free Radic Biol Med 2010;48(9):1252-62.
  pubmed

• 8) Yamakura F, Kawasaki H. Post-translational modifications of superoxide dismutase. Biochim Biophys Acta 2010;1804(2):318-25.
  pubmed

• 9) Koike M et al. Superoxide dismutase activity is significantly lower in end-stage osteoarthritic cartilage than non-osteoarthritic cartilage. PloS One 2018;13(9):e0203944.
  pubmed

• 10) Sinaki M. Exercise for patients with osteoporosis:management of vertebral compression fractures and trunk strengthening for fall prevention. PM R 2012;4(11):882-8.
  pubmed

• 11) Hongo M et al. Effect of low-intensity back exercise on quality of life and back extensor strength in patients with osteoporosis:a randomized controlled trial. Osteoporos Int 2007;18(10):1389-95.
  pubmed

P.73 掲載の参考文献

• 1) Broekmans FJ et al. Ovarian aging:mechanisms and clinical consequences. Endocr Rev 2009;30(5):465-93.
  pubmed

• 2) Strauss JF 3rd and Williams CJ. Ovarian Life Cycle. Strauss JF 3rd and Barbieri RL. Yen & Jaffe's Reproductive Endocrinology. 8th ed. ELSEVIER;2019. p.167-205.

• 3) Jones KT. Meiosis in oocytes:predisposition to aneuploidy and its increased incidence with age. Hum Reprod Update 2008;14(2):143-58.
  pubmed

• 4) 日本産科婦人科学会生殖補助医療(ART)データ登録, 2016.

• 5) te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update 2002;8(2):141-54.
  pubmed

• 6) Wood MA, Rajkovic A. Genomic markers of ovarian reserve. Semin Reprod Med 2013;31(6):399-415.
  pubmed

• 7) Warburton D. Biological aging and the etiology of aneuploidy. Cytogenet Genome Res 2005;111(3-4):266-72.

• 8) Briley SM et al. Reproductive age-associated fibrosis in the stroma of the mammalian ovary. Reproduction 2016;152(3):245-60.
  pubmed

• 9) May-Panloup P et al. Ovarian ageing:the role of mitochondria in oocytes and follicles. Hum Reprod Update 2016;22(6):725-43.
  pubmed

• 10) Fleming TP et al. Origins of lifetime health around the time of conception:causes and consequences. Lancet 2018;391(10132):1842-52.
  pubmed

• 11) Dechanet C et al. Effects of cigarette smoking on reproduction. Hum Reprod Update 2011;17(1):76-95.
  pubmed

• 12) Luke B et al. Female obesity adversely affects assisted reproductive technology(ART)pregnancy and live birth rates. Hum Reprod 2011;26:245-52.
  pubmed

• 13) Wu LL et al. Mitochondrial dysfunction in oocytes of obese mothers:transmission to offspring and reversal by pharmacological endoplasmic reticulum stress inhibitors. Development 2015;142(4):681-91.
  pubmed

• 14) Takahashi N et al. A Potential Role for Endoplasmic Reticulum Stress in Progesterone Deficiency in Obese Women. Endocrinology 2017;158(1):84-97.
  pubmed

• 15) Loh JS, Maheshwari A. Anti-Mullerian hormone--is it a crystal ball for predicting ovarian ageing? Hum Reprod 2011;26(11):2925-32.
  pubmed

• 16) Meldrum DR et al. Aging and the environment affect gamete and embryo potential:can we intervene? Fertil Steril 2016;105(3):548-59.
  pubmed

• 17) Tamura H et al. Long-term melatonin treatment delays ovarian aging. J Pineal Res 2017;62(2).
  pubmed

• 18) Akino N et al. Activation of Nrf2/Keap1 pathway by oral Dimethylfumarate administration alleviates oxidative stress and age-associated infertility might be delayed in the mouse ovary. Reprod Biol Endocrinol 2019;17(1):23.
  pubmed

• 19) Takahashi N et al. Activation of Endoplasmic Reticulum Stress in Granulosa Cells from Patients with Polycystic Ovary Syndrome Contributes to Ovarian Fibrosis. Sci Rep 2017;7(1):10824.
  pubmed

• 20) Merhi Z. Advanced glycation end products and their relevance in female reproduction. Hum Reprod 2014;29(1):135-45.
  pubmed

P.78 掲載の参考文献

• 1) Bagatell CJ, Bremner WJ. Androgens in men:uses and abuses. N Engl J Med 1996;334:707-14.
  pubmed

• 2) Kuohung W, Kaiser UB. GPR54 and KiSS-1:role in the regulation of puberty and reproduction. Rev Endocr Metab Disord 2006;7:257-63.
  pubmed

• 3) Morley JE, Perry HM 3rd. Andropause:an old concept in new clothing. Clin Geriatr Med 2003;19:507-28.

• 4) Gunes S et al. Effects of aging on the male reproductive system. J Assist Reprod Genet 2016;33:441-54.
  pubmed

• 5) 小堀善友, 岡田弘. 精巣・精子のアンチエイジング. 臨床泌尿器科2013;67:1067-71.

• 6) Humm KC, Sakkas D. Role of increased male age in IVF and egg donation:is sperm DNA fragmentation responsible? Ferteil Steril 2013;99:30-6.
  pubmed

• 7) Hayakawa T et al. Significant changes in volume of seminal vesicles as deter-mined by transrectεd sonography in relation to age and benign prostatic hyperplasia. Tohoku J Exp Med 1998;186:193-204.

• 8) 日本泌尿器科学会, 他(編). 加齢男性性腺機能低下症候群-LOH症候群-診療の手引き. じほう;2007.

• 9) Ide H et al. Diabetes and LOH syndrome, Springer Nature, 2018:167-76.

• 10) Srinivas-Shankar U et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men:a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010;95:639-50.

• 11) Allan CA, McLachlan RI. Androgens and obesity. Curr Opin Endocrinol Diabetes Obes 2010;17:224-32.
  pubmed

• 12) Zou P et al. Semen Quality in Chinese College Students:Associations With Depression and Physical Activity in a Cross-Sectional Study. Psychosom Med 2018;80:564-72.

• 13) Sharma R et al. Cigarette Smoking and Semen Quality:A New Meta-analysis Examining the Effect of the 2010 World Health Organization Laboratory Methods for the Examination of Human Semen. Eur Urol 2016;70:635-45.

• 14) Ricci E et al. Semen quality and alcohol intake:a systematic review and meta-analysis. Reprod Biomed Online 2017;34:38-47.
  pubmed

• 15) Wang Y et al. Steroidogenesis in Leydig cells:effects of aging and environmental factors. Reproduction 2017;154:R111-22.
  pubmed

• 16) Kobori Y et al. Antioxidant cosupplementation therapy with vitamin C, vitamin E, and coenzyme Q10 in patients with oligoasthenozoospermia. Arch Ital Urol Androl 2014;86:1-4.
  pubmed

• 17) Juan ME et al. trans-Resveratrol, a natural antioxidant from grapes, increases sperm output in healthy rats. J Nutr 2005;135:757-60.
  pubmed

• 18) Fukuhara S et al. Vardenafil and resveratrol synergistically enhance the nitric oxide/cyclic guanosine monophosphate pathway in corpus cavernosal smooth muscle cells and its therapeutic potential for erectile dysfunction in the streptozotocin-induced diabetic rat:preliminary findings. J Sex Med 2011;8:1061-71.
  pubmed

• 19) Ledda A et al. Investigation of a complex plant extract for mild to moderate erectile dysfunction in a randomized, double-blind, placebo-controlled, parallel-arm study. BJU Int 2010;106:1030-3.

• 20) Aoki H et al. Clinical assessment of a supplement of Pycnogenol(R) and L-arginine in Japanese patients with mild to moderate erectile dysfunction. Phytother Res 2012;26:204-7.

• 21) Kobori Y et al. Improvement of seminal quality and sexual function of men with oligoasthenoteratozoospermia syndrome following supplementation with L-arginine and Pycnogenol(R). Arch Ital Urol Androl 2015;87:190-3.

ライフスタイル・食事

P.86 掲載の参考文献

• 1) 奥井伸雄. 運動の指標としての, テストステロンと性機能評価～運動での突然死, 競技成績などに関する考察～. 日本性機能学会雑誌 2017;32:27-34.
  Medical*Online

• 2) 奥井伸雄. 長距離走は低テストステロンを招く. 神奈川医会誌 2016;43:19-22.

• 3) 奥井伸雄. 運動ストレス性低テストステロン症(ESLT)に対する漢方の効果-スポーツと漢方治療の有効性の考察. 漢方と最新治療 2018;27:87-91.
  Medical*Online

• 4) 奥井伸雄. 運動ストレス性低テストステロン症. 臨床泌尿器科2019;73(印刷中)

• 5) 奥井伸雄. ウォーキングと去勢抵抗性前立腺がん発症の関係についての研究. 腎臓内科・泌尿器科 2018;8:183-90.

• 6) Kenfield SA et al. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol 2011;29:726-32.
  pubmed

• 7) Heitmann BL, Frederiksen P. Thigh circumference and risk of heart disease and premature death:prospective cohort study. BMJ 2009;339:b3292. doi:10.1136/bmj.b3292

P.93 掲載の参考文献

• 1) Lin SJ et al. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 2000;289(5487):2126-8.
  pubmed

• 2) Imai S et al. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000;403(6771):795-800.
  pubmed

• 3) Imai S. SIRT1 and Caloric Restriction:An insight into possible trade-offs between robustness and frailty. Curr Opin Clin Nutr Metab Care 2009;12(4):350-6.
  pubmed

• 4) Howitz KT et al. Small molecule activations of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003;425(6954):191-6.
  pubmed

• 5) Hands SL et al. mTOR's role in ageing:protein synthesis or autophagy? Aging 2009;1(7):586-97.
  pubmed

• 6) Lamming DW et al. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest 2013;123(3):980-9.
  pubmed

• 7) Bartke A and Brown-Borg H. Life extension in the dwarf mouse. Curr Top Dev Biol 2004;63:189-225.

• 8) Daitoku H and Fukamizu A. FOXO transcription factors in the regulatory networks of longevity. J Biochem 2007;141(6):769-74.
  pubmed

• 9) Colman RJ et al. Caloric restriction delays disease onset and mortality in rhesus monkey. Science 2009;325(5937):201-4.
  pubmed

• 10) Mattison JA et al. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 2012;489(7415):318-21.
  pubmed

• 11) Mattison JA et al. Caloric restriction improves health and survival of rhesus monkeys. Nat Commun 2017;8:14063.
  pubmed

• 12) Ravussin E et al. A 2-year Randomized controlled trial of human caloric restriction:feasibility and effects on predictors of health span and longevity. J Gerontol A Biol Sci Med Sci 2015;70(9):1097-104.
  pubmed

• 13) Nagai M et al. Association of total energy intake with 29-year mortality in the Japanese:NIPPON DATA80. J Atheroscler Thromb 2016;23(3):339-54.
  pubmed

• 14) Nakamura Y et al. Low-carbohydrate diets and cardiovascular and total mortality in Japanese:a 29-year follow-up of NIPPON DATA 80. Br J Nutr 2014;112(6):916-24.
  pubmed

• 15) Dehghan M et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents(PURE):a prospective cohort study. Lancet 2017;390(10107):2050-62.

• 16) Santos FL et al. Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. Obes Rev 2012;13(11):1048-66.
  pubmed

• 17) Yamada Y et al. A non-calorie-restricted low-carbohydrate diet is effective as an alternative therapy for patients with type 2 diabetes. Intern Med 2014;53(1):13-9.
  pubmed

• 18) Sato J et al. A randomized controlled trial of 130 g/day low-carbohydrate diet in type 2 diabetes with poor glycemic control. Clin Nutr 2017;36(4):992-1000.

• 19) Ozawa M et al. Dietary patterns and risk of dementia in an elderly Japanese population:the Hisayama study. Am J Clin Nutr 2013;97(5):1076-82.

• 20) Otsuka R et al. Cereal intake increases and dairy products decrease risk of cognitive decline among elderly female Japanese. J Prev Alzheimers Dis 2014;1(3):160-7.
  pubmed

• 21) Otsuka R et al. Dietary diversity decreases the risk of cognitive decline among Japanese older adults. Geriatr Gerontol Int 2017;17(6):937-44.
  pubmed

• 22) Otsuka R et al. Serum docosahexaenoic and eicosapentaenoic acid and risk of cognitive decline over 10 years among elderly Japanese. Eur J Clin Nutr 2014;68(4):503-9.
  pubmed

• 23) Ohara T et al. Glucose tolerance status and risk of dementia in the community:the Hisayama study. Neurology 2011;77(12):1126-34.
  pubmed

• 24) Puchalska P and Crawford PA. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and trerapeutics. Cell Metab 2017;25(2):262-84.
  pubmed

• 25) Cox PJ et al. Nutritional ketosis alters fuel preference and thereby endurance performance in athletes. Cell Metab 2016;24(2):256-68.
  pubmed

• 26) Murray AJ et al. Novel ketone diet enhances physical and cognitive performance. FASEB J 2016;30(12):4021-32.
  pubmed

• 27) Ota M et al. Effect of a ketogenic meal on cognitive function in elderly adults:potential for cognitive enhancement. Psychopharmacology 2016;233:3797-802.
  pubmed

P.102 掲載の参考文献

• 1) 消費者庁G「機能性食品」制度がはじまります!商品の開発・販売を考える前に. (https://www.caa.go.jp/policies/policy/food_labeling/about_foods_with_function_claims/pdf/150810_2.pdf)

• 2) 消費者庁. 機能性表示食品の届出等に関するガイドライン. (https://www.caa.go.jp/policies/policy/food_labeling/foods_with_function_claims/pdf/food_with_function_clains_171227_0001.pdf)

• 3) 消費者庁. 「機能性表示食品」って何?(https://www.caa.go.jp/policies/policy/food_labeling/about_foods_with_function_claims/pdf/150810_1.pdf)

P.110 掲載の参考文献

• 1) 厚生労働省. 調剤医療費(電算処理分)の動向～平成29年度版～.

• 2) 消費者庁. 機能性表示食品制度届け出データベース.

• 3) 厚生労働省. 平成29年「国民健康・栄養調査」の結果.

• 4) Whelton PK et al. Primary prevention of hypertension:clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002;288(15):1882-8.

• 5) 厚生労働省. 「日本人の食事摂取基準」(2015年版).

• 6) 梶本修身・他. GABA含有はっ酵乳製品の正常高値血圧者に対する降圧効果. 日本食品化学工学会誌 2004;51(2):79-86.

• 7) Li X, Xu J. Lycopene supplement and blood pressure:an updated meta-analysis of intervention trials. Nutrients 2013;5(9):3696-712.

• 8) McEneny J et al. Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals. J Nutr Biochem 2013;24(1):163-8.
  pubmed

• 9) Inmaculada Navarro-Gonzalez et al. The Inhibitory Effects of Bioactive Compounds of Tomato Juice Binding to Hepatic HMGCR:in vivo Study and Molecular Modelling. PLoS One 2014;9(1):e83968.

• 10) 石田優・他. 「ラクトトリペプチド(VPP, IPP)」を含有するタブレットの長期摂取が正常高値血圧者および軽症高血圧者に及ぼす影響. 薬理と治療2007;35(12):1249-60.

• 11) 梶本修身・他. イワシ由来ペプチド含有食品の正常高値血圧, 高血圧に対する効果. 健康・栄養食品研究 2003;6(2):65-82.

• 12) 越智大介・他. カゼイン由来トリペプチドMet-Lys-Proの正常高値血圧者およびI度高血圧者に対する血圧降下作用-ランダム化二重盲検プラセボ対照並行群間比較試験-薬理と治療 2017;45(10):1637-48.
  Medical*Online

• 13) 内田理一郎・他. 大豆発酵調味液(大豆ペプチド含有)配合減塩しょうゆの正常高値血圧者および軽症高血圧者に対する有効性と安全性. 薬理と治療 2008;36(9):837-50.
  Medical*Online

• 14) Maruyama S, Suzuki H. A Peptide Inhibitor of Angiotensin I Converting Enzyme in the Tryptic Hydrolysate of Casein. Agric biolal chem 1982;46(5):1393-4.

• 15) 里内美津子・他. 難消化性デキストリンのヒト便通に及ぼす影響. 栄養学雑誌 1993;51(1):31-7.

• 16) Unno T et al. Effects of green tea supplemented with indigestible dextrin on postprandial levels of blood glucose and insulin in human subjects. J Nutritional Food 2002;5(2):31-9.

• 17) Kisimoto Y et al. Suppressive effect of resistant maltodextrin on postprandial blood triacylglycerol elevation. Eur J Nutr 2007;46:133-8.

• 18) Yoshikawa M et al. Absolute stereostructure of potent α-glucosidase inhibitor, salacinol, with unique thiosugar sulfonium sulfate inner salt structure from Salacia reticulata. Bioorg Med Chem 2002;10(5):1547-54.

• 19) Bang HO et al. Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. Lancet 1971;1:1143-5.
  pubmed

• 20) Bang HO et al. The composition of the Eskimo food in north western Greenland. Am J Clin Nutr 1980;33:2657-61.
  pubmed

• 21) 藤本祐三・他. 血中中性脂肪値が高めの成人男女を対象としたエイコサペンタエン酸・ドコサヘキサエン酸含有飲料の12 週間連続摂取による血中中性脂肪値低減効果および安全性の検討. 日本臨床栄養学会雑誌 2011;33(3):120-35.
  Medical*Online

• 22) Sagara M et al. Effects of Docosahexaenoic Acid Supplementation on Blood Pressure, Heart Rate, and Serum Lipids in Scottish Men with Hypertension and Hypercholesterolemia. Int J Hypertens 2011;2011:809198.
  pubmed

• 23) Iketani T et al. Effect of eicosapentaenoic acid on central systolic blood pressure. Prostaglandins Leukot Essent Fatty Acids. 2013;88(2):191-5.
  pubmed

• 24) Johnson EJ et al. Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. Nutr Neurosci 2008;11(2):75-83.
  pubmed

• 25) Kondo T et al. Vinegar intake reduces body weight, body fat mass, and serum triglyceride levels in obese Japanese subjects. Biosci Biotechnol Biochem 2009;73(8):1837-43.
  pubmed

• 26) 遠藤美智子, 松岡孝. 食酢の食後血糖上昇抑制効果. 糖尿病2011;54(3):192-9.

• 27) 梶本修身・他. 食酢配合飲料の正常高値血圧者および軽症高血圧者に対する降圧効果. 健康・栄養食品研究 2003;6(1):51-68.

• 28) Ono T et al. Effects of pepsin and trypsin on the anti-adipogenic action of lactoferrin against pre-adipocytes derived from rat mesenteric fat. Br J Nutr 2011;105(2):200-11.
  pubmed

• 29) Ono T et al. Potent lipolytic activity of lactoferrin in mature adipocytes. Biosci Biotechnol Biochem 2013;77(3):566-71.
  pubmed

• 30) 植松大輔. イチョウ葉エキスの脳梗塞慢性期の局所脳循環動態に対する効果. 脳卒中 2000;22(2):313-9.
  Medical*Online

• 31) Kaschel R. Specific memory effects of Ginkgo biloba extract EGb 761 in middle-aged healthy volunteers. Phytomedicine 2011;18(14):1202-7.
  pubmed

アンチエイジング・クリニック

P.120 掲載の参考文献

• 1) Peltz-Sinvani N et al. Low ALT Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary Heart Disease Patients. J Gen Intern Med 2016(2):209-14.
  pubmed

• 2) Ericson JE et al. Skeletal concentrations of lead in ancient Peruvians. New Eng J Med 1979;300(17):946-51.
  pubmed

• 3) Diaz D et al. Chelation therapy to prevent diabetes-associated cardiovascular events. Curr Opin Endocrinol Diabetes Obes 2018(4):258-66.
  pubmed

• 4) Rudman D et al. Effects of human growth hormone in men over 60 years old. New Eng J Med 1990;323(1):1-6.
  pubmed

• 5) Kobori Y et al. Influence of serum homocysteine level on coronary atherosclerosis in Japanese. J Cardiol 2004;43(5):223-9.
  pubmed

• 6) Seshadri S et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. New Eng J Med 2002;346(7):476-83.
  pubmed

• 7) Schnyder G et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. New Eng J Med 2001;345(22):1593-600.
  pubmed

• 8) Dyerberg J et al. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? The Lancet 1978;2(8081):117-9.

• 9) Yokoyama M et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients(JELIS):a randomised open-label, blinded endpoint analysis. Lancet 2007;369(9567):1090-8.
  pubmed

• 10) Simopoulos AP. An Increase in the Omega-6/Omega-3 Fatty Acid Ratio Increases the Risk for Obesity. Nutrients. Multidisciplinary Digital Publishing Institute. 2016;8(3):128.

• 11) 山田佳彦, 関原久彦. DHEA の老年病予防効果. 日本老年医学会雑誌 2003;40:421-8.

• 12) Holick MF. Vitamin D deficiency. New Eng J Med 2007;357(3):266-81.
  pubmed

• 13) Garland CF et al. Meta-analysis of all-cause mortality according to serum 25-hydroxyvitamin D. Am J Public Health 2014;104(8):e43-50.
  pubmed

• 14) 満尾正. ビタミンD3欠乏症の診断と治療. 日本抗加齢医学会雑誌 2010;6(2):74-7.

• 15) 満尾正. 有害金属汚染の診断と治療. 日本抗加齢医学会雑誌 2010;6(5):85-92.

• 16) Clarke NE et al. Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. Am J Med Sci 1956;232:654-66.
  pubmed

• 17) Lamas GA et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction:the TACT randomized trial. Jama 2013;309:1241-50.
  pubmed

• 18) Lin J-L et al. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med 2003;348(4):277-86.
  pubmed

• 19) 満尾正. 有害金属汚染とキレーション治療. 日本抗加齢医学会雑誌 2008;4(6):27-34.

• 20) 満尾正. キレーション治療. 治療(増刊号) 2007;89:1533-45.

• 21) 細胞機能と代謝マップ. 東京化学同人1997;p.107.

• 22) Rozema TC. The protocol for the safe and effective administration of EDTA and other chelating agents for vascular disease, degenerative disease, and metal toxicity. Journal of Advancement in Medicine 1997;10(1):74

P.125 掲載の参考文献

• 1) Ohnishi K et al. Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell 2014 13;156(4):663-77

• 2) Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005;5(3):223-31.
  pubmed

• 3) Fraga MF et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 2005;102:10604-60.
  pubmed

• 4) Fenaux P et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes:a randomised, open-label, phase III study. Lancet Oncol 2009;10(3):223-32.
  pubmed

• 5) Samid D et al. Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv Exp Med Biol 1997;400A:501-5.
  pubmed

• 6) Adam L et al. Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7ras cells in vitro and in nude mice. Cancer Res 1995;55(22):5156-60.
  pubmed

• 7) Gilbert J et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001;7(8):2292-300.

• 8) Baker MJ et al. Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate. J Neurooncol 2002;59(3):239-42.

• 9) Sung MW et al. Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. Anticancer Res 2007;27(2):995-1001.
  pubmed

• 10) Chen Q et al. Pharmacological ascorbic concentration selectively kill cancer cell:action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005;102:13604-09,
  pubmed

• 11) Kawada H et al. High Concentrations of L-Ascorbic Acid Specifically Inhibit the Growth of Human Leukemic Cells via Downregulation of HIF-1a Transcription. Pros One 2013;8(4):e62717

• 12) Cimmino L et al. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. Cell 2017:170(6):1079-95

• 13) Jihye Y et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 2015;350(6266):1391-96.

• 14) Welsh JL et al. Pharmacological Ascorbate with Gemcitabine for the Control ofMetastatic and Node-Positive Pancreatic Cancer(PACMAN):Results from a Phase I Clinical Trial. Cancer Chemother Pharmacol 2013;71(3):765-75

• 15) Ma Y et al. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 2014;6(222):222ra18
  pubmed

• 16) Polireddy K et al. High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis:Mechanisms and a Phase I/IIa study. Sci Rep 2017;7(1):17188.

• 17) Tsuma-Kaneko M et al. Iron removal enhances vitaminC-induced apoptosis and growth inhibition of K-562 leukemic cells. Sci Rep 2018;8(1):17377

トピックス

P.131 掲載の参考文献

• 1) Moran CN et al. J Sports Sci 2017;35(14):1411-9.
  pubmed

• 2) Khera AV et al. Nat Genet 2018;50(9):1219-24.
  pubmed

• 3) Yokoyama A et al. Jpn J Clin Oncol 2003;33(3):111-21.
  pubmed

• 4) Ishiguro S et al. Cancer Lett 2009;275(2):240-6.
  pubmed

• 5) Heijmans BT et al. Proc Natl Acad Sci U S A 2008;105(44):17046-9.
  pubmed

• 6) Maeda M et al. Gut 2017;66(9):1721-3.
  pubmed

• 7) Lu AT et al. Aging(Albany NY). 2019;11(2):303-27.
  pubmed

• 8) Cavallari LH et al. JACC Cardiovasc Interv 2018;11(2):181-91.
  pubmed

• 9) Su-Yin DT. Eur Cardiol 2018;13(2):112-4.
  pubmed

• 10) Kalia SS et al. Genet Med 2017;19(2):249-55.

• 11) Momozawa Y. Nat Commun 2018;9(1):4083.
  pubmed

P.133 掲載の参考文献

• 1) 日本性機能学会, 日本泌尿器科学会編. ED診療ガイドライン[第3版]. リッチヒルメディカル;2018.

• 2) Gazzaruso C et al. Circulation 2004;110:22-6.
  pubmed

• 3) Kloner RA. Erectile dysfunction and cardiovascular risk factors. In:Kloner RA ed. Heart disease and erectile dysfunction. Humana Press Inc;2004. pp39.

• 4) Hall SA et al. Am J Cardiol 2010;105:192-7.
  pubmed

• 5) Herrmann HC et al. N Engl J Med 2000;342:1622-6.
  pubmed

• 6) Al-Ameri H et al. Int J Impot Res 2009;21:149-57.
  pubmed

• 7) Foresta C et al. Int J Impot Res 2006;18:484-8.
  pubmed

• 8) Rosano GM et al. Eur Urol 2005;47:214-20.
  pubmed

• 9) Porst H et al. J Sex Med 2013;10:2044-52.
  pubmed

• 10) Fukumoto K et al. Int J Urol 2017;24:206-10.
  pubmed

P.135 掲載の参考文献

• 1) 日本肥満学会編. 肥満症診療ガイドライン2016. ライフサイエンス出版, 2016.

• 2) Shirai K et al. The effects of partial use of formula diet on weight reduction and metabolic variables in obese type 2 diabetic patients--multicenter trial. Obes Res Clin Pract 2013;7(1):e43-54.
  pubmed

• 3) Matsuzaki T et al. Weight reduction using a formula diet recovers menstruation in obese patients with an ovulatory disorder. Reprod Med Biol 2017;16(3):268-75.
  pubmed

P.138 掲載の参考文献

• 1) 治京玉記. マカ(Lepidium meyenii WALP)の成分分析法について. 中村学園大学薬膳科学研究所研究紀要 2013;6:13-27.

• 2) Gonzales GF. Ethnobiology and Ethnopharmacology of Lepidium meyenii(Maca), a Plant from the Peruvian Highlands. Evid Based Complement Alternat Med 2012;2012:193496.

• 3) Soundararajan P, Kim JS. Anti-Carcinogenic Glucosinolates in Cruciferous Vegetables and Their Antagonistic Effects on Prevention of Cancers. Molecules 2018;23. E2983.

• 5) Aoki Y. Effect of Lepidium meyenii on in vitro fertilization via improvement in acrosome reaction and motility of mouse and human sperm. Reprod Med Biol 2018;1:57-64.
  pubmed

P.140 掲載の参考文献

• 1) Hatori M et al. NPJ Aging Mech Dis 2017;3:9.
  pubmed

• 2) Zielinska-Dabkowska KM. Nature 2018;18:274-6.

• 3) Noseda R et al. Nat Neurosci 2010;13:239-45.
  pubmed

• 4) Esquiva G et al. Front Aging Neurosci 2017;9:79.
  pubmed

• 5) Erichsen JH et al. Journal of Cataract & Refractive Surgery 2015;41:1997-2009.
  pubmed

• 6) Nissen C et al. Front Neurol 2014;5:15.
  pubmed

• 7) Perez-Rico et al. Exp Eye Res 2010;91:578-83.
  pubmed

• 8) Hatori M et al. Cell Metab 2012;15:848-60.
  pubmed